Using its chemoinformatics technologies, MolGenie has designed and synthesized novel, small molecule compounds as putative GPCR antagonists. With financial support […]
Category: our drug discovery
Cysteine Protease Inhibitors And Methods Of Use Thereof
We are pleased to report that the captioned application issued as U.S. Patent No. 12,077,605 as an electronic patent grant […]
Novel targeted E7 protein degraders
A new PCT patent application claiming new viral protein E7 degraders has been published as WO2022219157A1. The invention was made […]
Anixa-MolGenie compounds are more potent than the protease inhibitor in Pfizer’s PAXLOVID™ at inhibiting the main protease of SARS-CoV-2
SAN JOSE, Calif. and STUTTGART, Germany, Jan. 24, 2022 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused […]
Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant
Dec. 7, 2021 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious […]
Anixa Biosciences’ Covid-19 Compounds Expected to be Effective Against the Delta Variant
While vaccination has proven to be an effective strategy to prevent Covid-19, the need exists for inexpensive, room-temperature stable, and […]
TUBE Pharmaceuticals and MolGenie collaborate
TUBE Pharmaceuticals GmbH in Vienna, Austria, has developed cytotoxic molecules that are derived from a class of natural products called […]
MolGenie develops new peptide-drug-conjugates (PDC)
MolGenie has currently been assigned the rights to develop and commercialize the rights to a EU-PCT patent application claiming treatments […]
OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie
HALLE (SAALE), Germany, May 7, 2021 /PRNewswire/ — OntoChem GmbH, a German Life Science IT company, announced today that it has assigned its drug […]